The company had posted a net profit of Rs 54.44 crore for the January-March period of the previous fiscal.
Net sales of the company rose to Rs 386.77 crore for the fourth quarter, as compared to Rs 190.57 crore for the same period of previous fiscal, Natco Pharma said in a regulatory filing.
"The key driver for the accelerated revenue growth was the company's Hepatitis C portfolio of products in the domestic Indian market," it added.
Net sales for the year ended march 31, 2016 rose to Rs 1,088.35 crore as against Rs 774.20 crore in the 2014-15 fiscal.
Shares of Natco Pharma today closed 2.38 per cent up at Rs 463.05 apiece on BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%